SG11201509680TA - Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate. - Google Patents

Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Info

Publication number
SG11201509680TA
SG11201509680TA SG11201509680TA SG11201509680TA SG11201509680TA SG 11201509680T A SG11201509680T A SG 11201509680TA SG 11201509680T A SG11201509680T A SG 11201509680TA SG 11201509680T A SG11201509680T A SG 11201509680TA SG 11201509680T A SG11201509680T A SG 11201509680TA
Authority
SG
Singapore
Prior art keywords
9alpha
oxoandrosta
6alpha
16alpha
methylbutyryloxy
Prior art date
Application number
SG11201509680TA
Other languages
English (en)
Inventor
Jiten Ranchhodbhai Patel
Gopalkumar Chimanlal Patel
Gaurav Sanjivkumar Sheth
Sanjay Nandlal Mandhane
Chitturi Trinadha Rao
Rajamannar Thennati
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of SG11201509680TA publication Critical patent/SG11201509680TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SG11201509680TA 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate. SG11201509680TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1881MU2013 2013-05-28
PCT/IN2014/000359 WO2014192027A1 (en) 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Publications (1)

Publication Number Publication Date
SG11201509680TA true SG11201509680TA (en) 2015-12-30

Family

ID=51300796

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509680TA SG11201509680TA (en) 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Country Status (18)

Country Link
US (1) US9458187B2 (zh)
EP (1) EP3004133B1 (zh)
JP (1) JP6366696B2 (zh)
KR (1) KR20160030085A (zh)
CN (1) CN105431445A (zh)
AU (1) AU2014272640B2 (zh)
BR (1) BR112015029530A8 (zh)
CA (1) CA2912400A1 (zh)
EA (1) EA027831B9 (zh)
ES (1) ES2664019T3 (zh)
IL (1) IL242658A0 (zh)
MX (1) MX2015016283A (zh)
MY (1) MY179214A (zh)
PH (1) PH12015502652A1 (zh)
SG (1) SG11201509680TA (zh)
UA (1) UA117248C2 (zh)
WO (1) WO2014192027A1 (zh)
ZA (1) ZA201508640B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431445A (zh) 2013-05-28 2016-03-23 太阳医药高级研究有限公司 使用S-[4-(3-氟-3-甲基丁酰氧基)丁-2-炔基]6α,9α-二氟-17α-(呋喃-2-基)羰氧基-11β-羟基-16α-甲基-3-氧代雄甾-1,4-二烯-17β-硫代羧酸酯治疗炎性疾病的方法
SG11201706104XA (en) * 2015-01-31 2017-08-30 Sun Pharma Advanced Res Co Ltd CRYSTALLINE FORM OF S-(4-(3-FLUORO-3-METHYLBUTYRYLOXY)BUT-2-YNYL)6a,9a-DIFLUORO-17a,-(FURAN-2-YL)CARBONYLOXY-11ß-HYDROXY-16a-METHY1-3-OXOANDROSTA-1,4-DIENE-17ß-CARBOTHIOATE
CN106279341A (zh) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 一种糠酸氟替卡松的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335121A (en) 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
US7208613B2 (en) 2002-06-20 2007-04-24 Sun Pharmaceutical Industries Limited Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
AR059216A1 (es) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
CN105431445A (zh) 2013-05-28 2016-03-23 太阳医药高级研究有限公司 使用S-[4-(3-氟-3-甲基丁酰氧基)丁-2-炔基]6α,9α-二氟-17α-(呋喃-2-基)羰氧基-11β-羟基-16α-甲基-3-氧代雄甾-1,4-二烯-17β-硫代羧酸酯治疗炎性疾病的方法

Also Published As

Publication number Publication date
BR112015029530A8 (pt) 2019-12-17
JP2016520122A (ja) 2016-07-11
EA201592283A1 (ru) 2016-04-29
EA027831B9 (ru) 2017-12-29
AU2014272640B2 (en) 2018-04-05
US20160102117A1 (en) 2016-04-14
KR20160030085A (ko) 2016-03-16
IL242658A0 (en) 2016-02-01
WO2014192027A1 (en) 2014-12-04
PH12015502652A1 (en) 2016-03-07
AU2014272640A1 (en) 2015-11-26
UA117248C2 (uk) 2018-07-10
JP6366696B2 (ja) 2018-08-01
EP3004133A1 (en) 2016-04-13
ES2664019T3 (es) 2018-04-18
MY179214A (en) 2020-11-02
EA027831B1 (ru) 2017-09-29
MX2015016283A (es) 2016-03-11
BR112015029530A2 (pt) 2017-07-25
CN105431445A (zh) 2016-03-23
CA2912400A1 (en) 2014-12-04
EP3004133B1 (en) 2018-03-07
ZA201508640B (en) 2017-09-27
US9458187B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
IL243976B (en) kdm1a inhibitors for disease treatment
HK1215378A1 (zh) 藥物組合物、治療方法及其用途
EP3027192A4 (en) Methods for the treatment of solid tumors
PL3030663T3 (pl) Kompozycje i sposoby kontroli leptinotarsa
EP3019491A4 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
DK2988743T3 (da) Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
SG11201600918PA (en) Method for authenticating transactions
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
EP2945639A4 (en) METHOD FOR THE TREATMENT OF HEART DISEASES
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
EP2945643A4 (en) Therapeutic agents, compositions, and methods for glycemic control
EP3307068A4 (en) Mct4 inhibitors for treating disease
EP3316887A4 (en) GLS1-INHIBITOR TO TREAT DISEASES
SG11201507352YA (en) Methods for purifying 5-(halomethyl)furfural
PL3046914T3 (pl) Sposoby wytwarzania 5-(halogenometylo)furfuralu
AP2015008803A0 (en) Methods for treating psoriasis using an anti-il-23antibody
FI20135921A (fi) Menetelmä metallien käsittelemiseksi
AU2014306716B2 (en) Compositions and methods for treating celiac sprue disease
EP3362205A4 (en) METHODS FOR IMPROVING THERMAL TREATMENT OF CAST PARTS
EP3082841A4 (en) Methods for treating an animal
ZA201508640B (en) Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate
EP3054022A4 (en) Method for thermally treating ring-shaped member
WO2014140856A3 (en) Mir-142 and antagonists thereof for treating disease
PL2964607T3 (pl) Sposób wytwarzania halogeno-n,n-dimetylobenzyloamin